TALTZ (ixekizumab)

Self-Administration – subcutaneous (SC) injection by prefilled autoinjector and prefilled syringe

Office-Administration - subcutaneous (SC) injection by prefilled syringe (doses of 20 mg or 40 mg must be prepared and administered by a qualified healthcare professional).

 

Indications for Prior Authorization:

 

Plaque Psoriasis (PsO): Indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Psoriatic Arthritis (PsA): Indicated for the treatment of adult patients with active psoriatic arthritis. 

Ankylosing Spondylitis (AS): Indicated for the treatment of adult patients with active ankylosing spondylitis. 

Non-radiographic Axial Spondyloarthritis (nr-axSpA): Indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.

 

Coverage Criteria:

 

For diagnosis of plaque psoriasis (PsO):

  • Documented diagnosis of moderate to severe PsO; AND
  • Prescribed by or in consultation with a dermatologist; AND
  • One of the following:
    • Greater than or equal to 3% body surface area involvement 
    • Severe scalp psoriasis 
    • Palmoplantar (i.e., palms, soles), facial, or genital involvement; AND
  • Minimum duration of a 4-week trial and failure, contraindication, or intolerance to one of the following topical therapies: 
    • corticosteroids (e.g., betamethasone, clobetasol) 
    • vitamin D analogs (e.g., calcitriol, calcipotriene) 
    • tazarotene 
    • calcineurin inhibitors (e.g., tacrolimus, pimecrolimus) 
    • anthralin 
    • coal tar; AND
  • One of the following:
    • Trial and failure, contraindication, or intolerance to ONE of the following: 
      • Cimzia (certolizumab pegol) 
      • Enbrel (etanercept) 
      • Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz
      • Skyrizi (risankizumab) 
      • Stelara (ustekinumab) 
      • Tremfya (guselkumab)
    • For continuation of prior Taltz therapy, defined as no more than a 45-day gap in therapy

 

For diagnosis of psoriatic arthritis (PsA):

  • Documented diagnosis of active PsA; AND
  • Prescribed by or in consultation with a rheumatologist or dermatologist; AND
  • One of the following:
    • actively inflamed joints 
    • dactylitis 
    • enthesitis 
    • axial disease 
    • active skin and/or nail involvement; AND
  • One of the following:
    • Trial and failure, contraindication, or intolerance to ONE of the following: 
      • Cimzia (certolizumab pegol)
      • Enbrel (etanercept)
      • Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz
      • Simponi (golimumab)
      • Stelara (ustekinumab)
      • Tremfya (guselkumab)
      • Skyrizi (risankizumab-rzaa)
      • Rinvoq (upadacitinib)
      • Xeljanz/XR (tofacitinib/ER)
    • For continuation of prior Taltz therapy, defined as no more than a 45-day gap in therapy

 

For diagnosis of ankylosing spondylitis (AS):

  • Documented diagnosis of active AS; AND
  • Prescribed by or in consultation with a rheumatologist; AND
  • Minimum duration of one-month trial and failure, contraindication, or intolerance to TWO different nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen, indomethacin, meloxicam, diclofenac) at maximally tolerated doses; AND
  • One of the following:
    • Trial and failure, contraindication, or intolerance to ONE of the following, or attestation demonstrating a trial may be inappropriate*: 
      • Cimzia (certolizumab pegol)
      • Enbrel (etanercept)
      • Humira (adalimumab), Amjevita, Cyltezo, Hyrimoz (Sandoz manufacturer), or Brand Adalimumab-adaz
      • Simponi (golimumab)
      • Rinvoq (upadacitinib)
      • Xeljanz/XR (tofacitinib/ER)
    • For continuation of prior Taltz therapy, defined as no more than a 45-day gap in therapy.

* Includes attestation that a total of two TNF inhibitors have already been tried in the past, and the patient should not be made to try a third TNF inhibitor.

 

For diagnosis of Non-radiographic Axial Spondyloarthritis (nr-axSpA):

  • Documented diagnosis of active nr-axSpA; AND
  • Prescribed by or in consultation with a rheumatologist; AND
  • Patient has objective signs of inflammation (e.g. C-reactive protein [CRP] levels above the upper limit of normal, or sacroiliitis on magnetic resonance imaging [MRI], indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints); AND
  • Minimum duration of one-month trial and failure, contraindication, or intolerance to TWO different nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen, naproxen, indomethacin, meloxicam, diclofenac) at maximally tolerated doses; AND
  • One of the following:
    • Trial and failure, contraindication, or intolerance to ONE of the following:
      • Cimzia (certolizumab pegol)
      • Rinvoq (upadacitinib) †
    • For continuation of prior Taltz therapy, defined as no more than a 45-day gap in therapy.

Requires inadequate response or intolerance to one or more TNF-inhibitors.

 

Reauthorization Criteria:

 

For diagnosis of PsO:

  • Documentation of positive clinical response to therapy as evidenced by one of the following:
    • Reduction the body surface area (BSA) involvement from baseline 
    • Improvement in symptoms (e.g., pruritus, inflammation) from baseline 

 

For diagnosis of PsA:

  • Documentation of positive clinical response to therapy as evidenced by at least one of the following: 
    • Reduction in the total active (swollen and tender) joint count from baseline 
    • Improvement in symptoms (e.g., pain, stiffness, pruritus, inflammation) from baseline 
    • Reduction in the body surface area (BSA) involvement from baseline 

 

For diagnosis of AS:

  • Documentation of positive clinical response to therapy as evidenced by improvement from baseline for least one of the following: 
    • Disease activity (e.g., pain, fatigue, inflammation, stiffness) 
    • Lab values (erythrocyte sedimentation rate, C-reactive protein level) 
    • Function 
    • Axial status (e.g., lumbar spine motion, chest expansion) 
    • Total active (swollen and tender) joint count 

 

For diagnosis of nr-axSpA:

  • Documentation of positive clinical response to therapy as evidenced by improvement from baseline for least one of the following: 
    • Disease activity (e.g., pain, fatigue, inflammation, stiffness) 
    • Function 
    • Lab values (erythrocyte sedimentation rate, C-reactive protein level) 
    • Axial status (e.g., lumbar spine motion, chest expansion) 
    • Total active (swollen and tender) joint count 

 

Dosing:

 

PsO (adults and pediatrics 6 years of age or older):

  • Adults:
    • 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
  • Pediatric, 6 to 17 years old:
    • less than 25 kg: 40 mg by subcutaneous injection at Week 0, followed by 20 mg every 4 weeks.
    • 25 kg to 50 kg: 80 mg by subcutaneous injection at Week 0, followed by 40 mg every 4 weeks.
    • greater than 50 kg: 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.

PsA (adults):

  • 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.
  • PsA with coexistent moderate-to-severe PsO: 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.

AS (adults):

  • 160 mg by subcutaneous injection (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks.

nr-axSpA (adults):

  • 80 mg by subcutaneous injection every 4 weeks.

 

Coverage Duration:

 

PsO, PsA, AS, nr-axSpA:

  • Initial: 1 year
  • Reauthorization: 1 year

 

Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

 

Additional Information:
  • Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. 
  • Taltz may increase the risk of infection. 
  • Patients treated with Taltz may be at increased risk of inflammatory bowel disease. During Taltz treatment, monitor for onset or exacerbation of inflammatory bowel disease.
  • Avoid the use of live vaccines in patients treated with Taltz.
  • Taltz doses of 20 mg or 40 mg must be prepared and administered by a qualified healthcare professional. Use only the commercial Taltz 80 mg/1 mL prefilled syringe when preparing the prescribed 20 mg and 40 mg pediatric dose.

 

Review History:
  • 10/20/2020 - Original review.
  • 02/16/2021 - Annual review.  Criteria and format updated; P&T Ad Hoc review of PA guidelines: removed reference to chart note requirement; removed TB testing requirements; added medical necessity guidance for reauthorization requests; updated approval duration to 1 year.
  • 04/20/2021 - Removed prerequisite for one TNF-blocker for UC and CD.
  • 01/01/2023 - Update prerequisite drugs for PsO, PsA, AS, nr-axSpA; add symptom requirements for PsO, PsA; add reauthorization criteria for all indications. (P&T 11/15/2022)
  • 09/01/2023 - Addition of Amjevita, Cyltezo, Hyrimoz, and brand Adalimumab-adaz as preferred step options for PsO, PsA, and AS. (P&T date on 08/15/2023)
  • 11/14/2023 – Update Hyrimoz preferred agent to Sandoz manufacturer only.

 

References:
  1. Taltz prescribing information. Eli Lilly and Company. Indianapolis, IN. May 2022. 
  2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol 2019;80:1029-72. 
  3. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70. 
  4. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5-32. 
  5. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-1613.

Last review date: November 14, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone